Last reviewed · How we verify
TRYP-0082
At a glance
| Generic name | TRYP-0082 |
|---|---|
| Also known as | Psilocybin |
| Sponsor | TRYP Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) (PHASE2)
- Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRYP-0082 CI brief — competitive landscape report
- TRYP-0082 updates RSS · CI watch RSS
- TRYP Therapeutics portfolio CI